A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma.

Can J Gastroenterol Hepatol · 2018 · PMC5829312 · PMID 29623263

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

showed a trend towards improvement in OS (7.1 versus 6.2 months, p = 0.08) and 12-month progression-free survival (PFS) (13.9 versus 8.4%, p = 0.004) with the use of gemcitabine plus capecitabine [ 9 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.